BCL2 and acute myeloid leukemia: By simultaneously targeting MCL-1, resistance to Venetoclax may be avoided, and we and other groups have reported that dual targeting of BCL-2 and MCL-1 in AML produces an enhanced cell killing response [11, 32–34].